RxDoctor Payments Data

Hadeel Barrawi, DO

Family Medicine · Grand Blanc, MINPI 1366063927

Payments from drug & device makers

$1,647in general payments, 2019–2025

Across 69 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$174
  • Novo Nordisk$169
  • Dexcom, Inc.$147
  • GSK$142
  • Lilly USA, LLC$136
  • Otsuka America Pharmaceutical, Inc.$134
  • plus $746 from 16 others

What the payments were for

  • Food & beverage$1,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$108,986
Medicare patients
266
Services billed
2,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide211$255,540
MounjaroTirzepatide64$68,304
JardianceEmpagliflozin29$46,414
EliquisApixaban27$34,325
MyrbetriqMirabegron14$13,406
TrulicityDulaglutide12$9,861
Mirabegron ErMirabegron12$6,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,114
SymbicortBudesonide/Formoterol Fumarate17$4,094
SynthroidLevothyroxine Sodium21$2,154
Rosuvastatin Calcium138$1,987
Levothyroxine Sodium187$1,946
ValacyclovirValacyclovir Hcl21$1,862
Gabapentin88$1,848
Atorvastatin Calcium224$1,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$169$255,540211 claims
Lilly USA, LLCMounjaro, Trulicity$136$78,16576 claims
Boehringer IngelheimJardiance$31$46,41429 claims
PfizerEliquis$174$34,32527 claims
AstraZenecaSymbicort$40$4,09417 claims
AbbVieSynthroid$74$2,15421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →